Global Rock Crusher Market By 2030

1.     +1 217 636 3356 +44 20 3289 9440 sales@mobilityforesights.com    Your Cart 0   Company Market Reports Consumer Research Advisory Services Exports - Imports Careers Contact Us Blog Your cart is empty Your Name Return to Shop Business Email Global Drug-Coated Stents Market 2024-2030 Country Phone Number +82 Company Name Single User License : $ 3,500 Your message Corporate User License : $ 6,000 By submitting this form, you are agreeing to the  Request Sample Terms of Use and Privacy Policy. I'm not a robot reCAPTCHA Privacy - Terms BUY NOW DOWNLOAD SAMPLE DESCRIPTION TABLE OF CONTENTS DRUG-COATED STENTS MARKET INTRODUCTION Drug-eluting stents have revolutionized the field of interventional cardiology, providing significant advances in the treatment of coronary artery disease. These special medical devices are used to treat blockages in arteries and are coated with drugs to prevent restenosis or re-narrowing of the artery after stenting. Drug-eluting stents have become a widely used technology in the fight against heart disease because they can improve long- term outcomes and reduce the need for repeat procedures. Coronary artery disease occurs when the arteries that supply blood to the heart become narrowed or blocked due to plaque buildup. Stents are small mesh tubes that are inserted into damaged arteries to open them up and restore blood flow. However, traditional metal stents had limitations as they were prone to restenosis. This led to the development of drug-eluting stents, which solve this problem by releasing drugs directly into the artery. The medicated coating of these stents serves two main purposes. First, it acts as an anti-proliferative agent that inhibits cell growth, which can lead to restenosis. By preventing excessive tissue growth, drug-coated stents help maintain the patency of the treated artery over time. Second, the drug coating reduces inflammation at the stent site and further reduces the risk of restenosis. This dual function significantly reduces the likelihood of repeated blockages and the need for additional procedures. Paclitaxel and sirolimus were the first two drugs widely used in drug-eluting stents. Paclitaxel blocks cell division, while sirolimus blocks signals that stimulate cell growth. These drugs are incorporated in a polymer matrix that covers the surface of the stent. When a stent is placed in a narrowed artery, the drug is gradually released over a period of time, ensuring that its therapeutic effect is maintained. We use cookies to understand site usage and improve content and offerings on our site. To learn more, refer to our Privacy Policy. By continuing to use this site, or closing this box, The use of drug-eluting stents has shown significant benefits in clinical trials and real-world practice. Studies have shown that 0 restenosis rates are significantly lower compared to bare metal stents.  Learn more you consent to our use of cookies. In addition, the need for repeated interventions such as balloon angioplasty or bypass surgery is greatly reduced with drug- Got it! eluting stents, improving patient outcomes and reducing healthcare costs. Continue Shopping DRUG-COATED STENTS MARKET SIZE AND FORECAST The Global Drug-Coated Stents Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030. DRUG-COATED STENTS MARKET NEW PRODUCT LAUNCH SLENDER Sirolimus-Eluting Coronary Stent Integrated Delivery System SLENDER Sirolimus-Eluting Coronary Stent Integrated Delivery System is a cobalt-chromium alloy stent coated with sirolimus drug and a bioresorbable polymer coating (PEA). The stent is advanced into the coronary artery using a catheter delivery system. Sirolimus is released from the stent over time, helping to prevent restenosis (narrowing of the artery). The PEA coating is designed to dissolve over time without leaving a permanent metal stent in the body. DIRECT Sirolimus-Eluting Coronary Stent Rapid Replacement System The DIRECT Sirolimus-Eluting Coronary Stent Rapid Exchange System is a similar device to the SLENDER stent, but is designed for rapid exchange. This means that if the first stent does not fit, it can be removed and replaced with another stent without having to re-enter the artery. Sorbic GT1 bioresorbable vascular scaffold system The Absorb GT1 Bioresorbable Vascular Scaffold System is a fully absorbable stent made of poly(L-lactide) polymer. The stent is coated with the drug Ever glue, which helps prevent restenosis. The Absorb stent is gradually absorbed into the body over 3 years. SYNERGY Bioresorbable vascular support system The SYNERGY Bioresorbable Vascular Scaffold System is another fully absorbable stent made of poly(L-lactide-cohesion- caprolactone) polymer. The stent is coated with the drug Zotero limmus, which helps prevent restenosis. The SYNERGY stent is gradually absorbed into the body over 2 years. THIS DRUG-COATED STENTS MARKET REPORT WILL ANSWER FOLLOWING QUESTIONS 1. How many Drug-Coated Stents are manufactured per annum globally? Who are the sub-component suppliers in different regions? 2. Cost breakup of a Global Drug-Coated Stents and key vendor selection criteria 3. Where is the Drug-Coated Stents manufactured? What is the average margin per unit? 4. Market share of Global Drug-Coated Stents market manufacturers and their upcoming products 5. Cost advantage for OEMs who manufacture Global Drug-Coated Stents in-house 6. key predictions for next 5 years in Global Drug-Coated Stents market 7. Average B-2-B Drug-Coated Stents market price in all segments 8. Latest trends in Drug-Coated Stents market, by every market segment 9. The market size (both volume and value) of the Drug-Coated Stents market in 2024-2030 and every year in between? 10. Production breakup of Drug-Coated Stents market, by suppliers and their OEM relationship. RELATED REPORTS

2. MARKET REPORTS CONSUMER RESEARCH INFORMATION ADVISORY SERVICES CONTACT INFORMATION  172/1, 2nd Floor, 5th Main, 9th Cross Rd, Opposite to Kairalee Nikethan Education Trust, Indira Nagar 1st Stage, Bengaluru, Karnataka 560038, INDIA  +1 217 636 3356, +44 20 3289 9440  sales@mobilityforesights.com Working Hours: Mon - Fri (9 AM - 9 PM IST) Connect with us     © Copyright 2017-2023. Mobility Foresights. All Rights Reserved.